Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | XmAb819 |
| Synonyms | |
| Therapy Description |
XmAb819 is a bispecific antibody that targets ENPP3 and CD3, potentially resulting in increased T-cell response against tumor cells expressing ENPP3 (NCI Drug Dictionary). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| XmAb819 | XmAb 819|XmAb-819|XmAb30819 | CD3 Antibody 119 ENPP3 Antibody 5 | XmAb819 is a bispecific antibody that targets ENPP3 and CD3, potentially resulting in increased T-cell response against tumor cells expressing ENPP3 (NCI Drug Dictionary). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05433142 | Phase I | XmAb819 | Study of XmAb819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma | Recruiting | USA | 0 |